Focused On-demand Library for Matrix metalloproteinase-19

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99542

UPID:

MMP19_HUMAN

Alternative names:

Matrix metalloproteinase RASI; Matrix metalloproteinase-18

Alternative UPACC:

Q99542; B4E030; O15278; O95606; Q99580

Background:

Matrix metalloproteinase-19 (MMP-19), also known as Matrix metalloproteinase RASI, plays a crucial role in degrading extracellular matrix components like aggrecan and cartilage oligomeric matrix protein. It is involved in various physiological processes including development, haemostasis, and pathological conditions such as arthritic disease. MMP-19's ability to hydrolyze key substrates like collagen type IV and laminin underscores its significance in tissue remodeling and disease.

Therapeutic significance:

MMP-19's involvement in cavitary optic disc anomalies, a condition leading to significant vision loss, highlights its potential as a therapeutic target. Understanding MMP-19's role could open doors to novel treatments for this and related ocular diseases, offering hope for patients suffering from profound central vision loss.